Precision oncolytic immunotherapy for mesothelioma and renal cell carcinoma

Bidragets beskrivning

Our immune system has the potential to protect us from cancer, but tumor cells have many strategies to hide from immune cells or turn off the immune attack. Immunotherapy is a way of helping our immune system to recognise the cancer and give it the right weapons to fight and destroy it. Immunotherapies have shown great promise and increased survival of cancer patients, but only for a fraction of patients. There is an urgent need for therapies that more precisely recognize a patient tumor, more efficient therapies that can overcome the tumor defence mechanisms and better pre-clinical models to test the therapies before they are used on patients. We have developed three novel technologies and a pipeline to address these challenges and aim to develop precision therapies against two tumor models, mesothelioma and renal cell carcinoma.
Visa mer

Startår

2023

Slutår

2027

Beviljade finansiering

Vincenzo Cerullo Orcid -palvelun logo
549 999 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiprojekt

Övriga uppgifter

Finansieringsbeslutets nummer

355107

Vetenskapsområden

Farmaci

Forskningsområden

Farmasia

Identifierade teman

cancer